183 related articles for article (PubMed ID: 10360609)
1. Phase II trial of 150-minute weekly infusion of gemcitabine in advanced colorectal cancer: minimal activity in colorectal cancer.
Mani S; Kugler JW; Knost JA; Sciortino DF; Gibbons J; Garcia JC; Ansari RH; Schilsky RL; Vokes EE
Invest New Drugs; 1998-1999; 16(3):275-8. PubMed ID: 10360609
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of gemcitabine in advanced colorectal adenocarcinoma.
Moore DF; Pazdur R; Daugherty K; Tarassoff P; Abbruzzese JL
Invest New Drugs; 1992 Nov; 10(4):323-5. PubMed ID: 1487408
[TBL] [Abstract][Full Text] [Related]
3. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
Mani S; Vogelzang NJ; Bertucci D; Stadler WM; Schilsky RL; Ratain MJ
Cancer; 2001 Sep; 92(6):1567-76. PubMed ID: 11745236
[TBL] [Abstract][Full Text] [Related]
4. Prolonged infusion of gemcitabine in stage IV breast cancer: a phase I study.
Akrivakis K; Schmid P; Flath B; Schweigert M; Sezer O; Mergenthaler HG; Possinger K
Anticancer Drugs; 1999 Jul; 10(6):525-31. PubMed ID: 10885899
[TBL] [Abstract][Full Text] [Related]
5. Paclitaxel and gemcitabine combination in a biweekly schedule in patients with advanced non small-cell lung cancer: a phase I study.
Athanasiadis A; Roussos G; Papakostoulis T; Athanasiadou DC; Stathopoulos GP
Cancer Chemother Pharmacol; 2005 Dec; 56(6):653-8. PubMed ID: 15937714
[TBL] [Abstract][Full Text] [Related]
6. Prolonged Pemetrexed Infusion Plus Gemcitabine in Refractory Metastatic Colorectal Cancer: Preclinical Rationale and Phase II Study Results.
Passardi A; Fanini F; Turci L; Foca F; Rosetti P; Ruscelli S; Casadei Gardini A; Valgiusti M; Dazzi C; Marangolo M
Oncologist; 2017 Aug; 22(8):886-e79. PubMed ID: 28592624
[TBL] [Abstract][Full Text] [Related]
7. Advanced breast cancer: a phase II trial with gemcitabine.
Carmichael J; Possinger K; Phillip P; Beykirch M; Kerr H; Walling J; Harris AL
J Clin Oncol; 1995 Nov; 13(11):2731-6. PubMed ID: 7595731
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer.
Penz M; Kornek GV; Raderer M; Ulrich-Pur H; Fiebiger W; Lenauer A; Depisch D; Krauss G; Schneeweiss B; Scheithauer W
Ann Oncol; 2001 Feb; 12(2):183-6. PubMed ID: 11300321
[TBL] [Abstract][Full Text] [Related]
9. Prolonged gemcitabine infusion in advanced non-small cell lung carcinoma: a randomized phase II study of two different schedules in combination with cisplatin.
Ceribelli A; Gridelli C; De Marinis F; Fabi A; Gamucci T; Cortesi E; Barduagni M; Antimi M; Maione P; Migliorino MR; Giannarelli D; Cognetti F
Cancer; 2003 Jul; 98(2):337-43. PubMed ID: 12872354
[TBL] [Abstract][Full Text] [Related]
10. A randomized phase II trial evaluating standard (50 mg/min) versus low (10 mg/min) infusion duration of gemcitabine as first-line treatment in advanced non-small-cell lung cancer patients who are not eligible for platinum-based chemotherapy.
Cappuzzo F; Novello S; De Marinis F; Selvaggi G; Scagliotti GV; Barbieri F; Maur M; Papi M; Pasquini E; Bartolini S; Marini L; Crinò L
Lung Cancer; 2006 Jun; 52(3):319-25. PubMed ID: 16630670
[TBL] [Abstract][Full Text] [Related]
11. Single-agent gemcitabine is active in previously treated metastatic breast cancer.
Spielmann M; Llombart-Cussac A; Kalla S; Espié M; Namer M; Ferrero JM; Diéras V; Fumoleau P; Cuvier C; Perrocheau G; Ponzio A; Kayitalire L; Pouillart P
Oncology; 2001; 60(4):303-7. PubMed ID: 11408796
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of gemcitabine as prolonged infusion in metastatic breast cancer.
Schmid P; Akrivakis K; Flath B; Grosse Y; Sezer O; Mergenthaler HG; Possinger K
Anticancer Drugs; 1999 Aug; 10(7):625-31. PubMed ID: 10507311
[TBL] [Abstract][Full Text] [Related]
13. A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity.
Borner MM; Bernhard J; Dietrich D; Popescu R; Wernli M; Saletti P; Rauch D; Herrmann R; Koeberle D; Honegger H; Brauchli P; Lanz D; Roth AD;
Ann Oncol; 2005 Feb; 16(2):282-8. PubMed ID: 15668285
[TBL] [Abstract][Full Text] [Related]
14. Concurrent infusional gemcitabine and radiation in the treatment of advanced unresectable GI malignancy: a phase I study.
Mohiuddin M; Kudrimoti M; Regine WF; McGrath PC; Hanna N; John W
Cancer J; 2002; 8(3):255-62. PubMed ID: 12074325
[TBL] [Abstract][Full Text] [Related]
15. Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer.
Rha SY; Moon YH; Jeung HC; Kim YT; Sohn JH; Yang WI; Suh CO; Kim GE; Roh JK; Chung HC
Breast Cancer Res Treat; 2005 Apr; 90(3):215-21. PubMed ID: 15830134
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine in patients with advanced malignant melanoma or gastric cancer: phase II studies of the EORTC Early Clinical Trials Group.
Sessa C; Aamdal S; Wolff I; Eppelbaum R; Smyth JF; Sulkes A; Ten Bokkel Huinink W; Vermorken J; Wanders J; Franklin H
Ann Oncol; 1994 May; 5(5):471-2. PubMed ID: 8075055
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of fixed dose rate infusion of gemcitabine in patients with unresectable pancreatic cancer.
Furuse J; Ishii H; Okusaka T; Nagase M; Nakachi K; Ueno H; Ikeda M; Morizane C; Yoshino M
Jpn J Clin Oncol; 2005 Dec; 35(12):733-8. PubMed ID: 16303793
[TBL] [Abstract][Full Text] [Related]
18. Prolonged infusion of gemcitabine in advanced solid tumors: a phase-I-study.
Schmid P; Schweigert M; Beinert T; Flath B; Sezer O; Possinger K
Invest New Drugs; 2005 Mar; 23(2):139-46. PubMed ID: 15744590
[TBL] [Abstract][Full Text] [Related]
19. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma.
Rothenberg ML; Cox JV; DeVore RF; Hainsworth JD; Pazdur R; Rivkin SE; Macdonald JS; Geyer CE; Sandbach J; Wolf DL; Mohrland JS; Elfring GL; Miller LL; Von Hoff DD
Cancer; 1999 Feb; 85(4):786-95. PubMed ID: 10091755
[TBL] [Abstract][Full Text] [Related]
20. [An early phase II study of gemcitabine hydrochloride (LY 188011). Gemcitabine Cooperative Study Group for Early Phase II].
Fukuoka M; Noda K; Hasegawa K; Nakajima H; Furuse K; Hirabayashi K; Hasegawa K; Ogura T; Niitani H; Taguchi T
Gan To Kagaku Ryoho; 1996 Nov; 23(13):1813-24. PubMed ID: 8937492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]